An Explosion of Diabetes Advances for You and Your Patients
Here’s what we expect from ADA 2026!
Diabetes science is accelerating exponentially and the 2026 ADA Scientific Sessions in New Orleans are set to surface a torpedo of new explosive data worth tracking. It’s the reason healthcare professionals across core subspecialties endocrinology, cardiology, hepatology, nephrology are watching for the full agenda to drop – the meeting consistently sets the direction for prescribing guidelines and clinical conversations the rest of the year. The 2026 Scientific Sessions will bring together more data on diabetes technology, the growing GLP-1 class of agents and indications across cardiac, hepatic, renal, and sleep medicine, fresh data on T-cell-directed therapies in type 1 diabetes (T1D), and a sharper picture of the cardiorenal hepatic axis as a single entity with therapeutic approaches. Drs. Steve Edelman and Jeremy Pettus sat down to map the four areas they’re watching most closely heading into the meetings.
The Hidden Cost of "Wait and See"
The overweight patient, recently diagnosed, on maximum metformin, with an A1C between 7.8 and 8.12%. You’ve seen this patient. You’ll probably see one this week.
What you may not see are the conditions already developing – cardiovascular risk, early kidney function decline – that won’t present with symptoms until they’re advanced. By the time GLP-1 therapy enters the picture for most of these patients, the window for prevention has narrowed considerably and the focus shifts to delaying the progression of possible complications.
In this discussion, Dr. Steve Edelman and Dr. Schafer Boeder challenge the conventional treatment timeline and make the case for rethinking when, not if, GLP-1 agents should be part of your approach
Meet Your Ultra-Experts
*extra-relatable faculty (he's living with type 1!)
Founder & Director, TCOYD; Endocrinologist, Clinical Professor of Medicine, University of California, San Diego (UCSD) School of Medicine; Director, Diabetes Care Clinic, VA Medical Center San Diego
Endocrinologist, Director of Type 1 Track and Professional Medical Education at TCOYD; Associate Professor of Medicine, UCSD School of Medicine, San Diego
Join Drs. Steve Edelman and Jeremy Pettus, and four impressive key opinion leaders for a fast-paced Diabetes Jeopardy face-off, accompanied by heavy appetizers, open bar, and the best networking of the ADA. Two decades of bringing the diabetes clinical community together on Sunday evening – and one of the most enjoyable nights on the meeting calendar. Ticket proceeds support the missions of TCOYD and diaTribe!
Are you going to ADA 2026?
Join Drs. Steve Edelman and Jeremy Pettus, and four impressive key opinion leaders for a fast-paced Diabetes Jeopardy face-off, accompanied by heavy appetizers, open bar, and the best networking of the ADA. Two decades of bringing the diabetes clinical community together on Sunday evening – and one of the most enjoyable nights on the meeting calendar. Ticket proceeds support the missions of TCOYD and diaTribe!
Leave a Reply